Literature DB >> 9174125

The efficacy of doxorubicin microspheres for hepatic micrometastases in a rat tumour model.

W J Esdale1, T L Walker, J White, E E DeCruz, M A Burton.   

Abstract

The use of sustained-release microspheres is of potential benefit as an adjuvant treatment for patients with occult hepatic micrometastases. This study investigates the response of a model of implantable adenocarcinoma micrometastases in the livers of DA rats following the intraportal injection of doxorubicin-incorporated ion-exchange microspheres compared to free drug bolus administration. A point-counting technique was used to determine the percentage of liver consisting of tumour 13 days after treatment. This was used as an indicator of tumour response, as was the derived tumour mass. There was a significantly higher tumour response in animals treated with the microspheres compared to animals treated with free drug delivered at the same concentration. This effect, however, was shown to decrease with a delay in the time of treatment. The tumour response of the sustained-release microspheres was achieved in the absence of any detectable local or systemic toxicity. This study demonstrates the potential of sustained-release microspheres in the treatment of patients with hepatic micrometastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174125     DOI: 10.1023/a:1018469314549

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  12 in total

1.  Evaluation of ion-exchange microspheres as carriers for the anticancer drug doxorubicin: in-vitro studies.

Authors:  Y Chen; M A Burton; J P Codde; S Napoli; I J Martins; B N Gray
Journal:  J Pharm Pharmacol       Date:  1992-03       Impact factor: 3.765

2.  Adjuvant therapy in bowel cancer: its time has arrived.

Authors:  B N Gray
Journal:  Aust N Z J Surg       Date:  1991-01

3.  Intra-operative ultrasound for the detection of hepatic metastases from colorectal cancer.

Authors:  P J Stewart; J M Chu; S C Kos; P H Chapuis; E L Bokey
Journal:  Aust N Z J Surg       Date:  1993-07

4.  Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.

Authors:  N Wolmark; H Rockette; D L Wickerham; B Fisher; C Redmond; E R Fisher; M Potvin; R J Davies; J Jones; A Robidoux
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

5.  Dose response and toxicity of doxorubicin microspheres in a rat tumor model.

Authors:  S Napoli; M A Burton; I J Martins; Y Chen; J P Codde; B N Gray
Journal:  Anticancer Drugs       Date:  1992-02       Impact factor: 2.248

6.  Reduced toxicity of adriamycin by incorporation into ion exchange microspheres: a therapeutic study using a rat liver tumour model.

Authors:  J P Codde; M A Burton; D K Kelleher; S G Archer; B N Gray
Journal:  Anticancer Res       Date:  1990 Nov-Dec       Impact factor: 2.480

7.  Comparison of portal vein chemotherapy with hepatic artery chemotherapy in the treatment of liver micrometastases.

Authors:  S G Archer; B N Gray
Journal:  Am J Surg       Date:  1990-03       Impact factor: 2.565

8.  A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.

Authors:  I Taylor; D Machin; M Mullee; G Trotter; T Cooke; C West
Journal:  Br J Surg       Date:  1985-05       Impact factor: 6.939

9.  Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial.

Authors:  J P Arnaud; M Buyse; B Nordlinger; F Martin; J C Pector; P Zeitoun; A Adloff; N Duez
Journal:  Br J Surg       Date:  1989-03       Impact factor: 6.939

10.  Practical stereological methods for morphometric cytology.

Authors:  E R Weibel; G S Kistler; W F Scherle
Journal:  J Cell Biol       Date:  1966-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.